BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG has reiterated its Buy rating on Perspective Therapeutics, setting a price target of $14.00. This target suggests a potential upside of 493.2% from the stock's previous closing price of $2.36 on October 6.